Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 10, 2004, Pages 4033-4036

  Credito, Kim ^a   Lin, Gengrong ^a   Ednie, Lois M ^a   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; ORITAVANCIN; PEPTIDE DEFORMYLASE INHIBITOR; RANBEZOLID; TEICOPLANIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; ENZYME INHIBITORS; HUMANS; PEPTIDES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 4644341060     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.10.4033-4036.2004     Document Type: Article

References (24)

1. Anderegg, T. R., D. J. Biedenbach, R. N. Jones, and the Quality Control Working Group. 2003. Quality control guidelines for MIC susceptibility testing of NVP-PDF 713: a novel peptide deformylase inhibitor. Int. J. Antimicrob. Agents 22:84-86.
2. Anderegg, T. R., R. N. Jones, and the Quality Control Working Group. 2004. Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor. Diagn. Microbiol. Infect. Dis. 48:55-57.
3. Biavasco, F., C. Vignarolli, R. Lupdi, E. Manso, B. Facinelli, and P. E. Varaldo. 1997. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob. Agents Chemother. 41:2165-2172.
4. Boucher, H. W., C. B. Wennersten, and G. M. Eliopoulos. 2000. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob. Agents Chemother. 44:2225-2229.
5. Bozdogan, B., D. Esel, C. Whitener, F. A. Browne, and P. C. Appelbaum. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52:864-868.
6. Cercenado, E., F. Garcia-Garrote, and E. Bouza. 2001. In-vitro activity of linezolid against multiply resistant gram-positive clinical isolates. J. Antimicrob. Chemother. 47:77-81.
7. Cuny, C., and W. Witte. 2000. In vitro activity of linezolid against staphylococci. Clin. Microbiol. Infect. 6:328-333.
8. Diekema, D. J., and R. N. Jones. 2000. Oxazolidinones. A review. Drugs 59:7-16.
9. Fritsche, T. R., G. J. Moet, and R. N. Jones. Commercial broth microdilution panel validation and reproducibility trials for NVP-PDF 713, a novel inhibitor of bacterial peptide deformylase. Clin. Microbiol. Infect., in press.
10. Henwood, C. J., D. M. Livermore, A. P. Johnson, D. James, M. Warner, A. Gardiner, and the Linezolid Study Group. 2000. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J. Antimicrob. Chemother. 46:931-940.
11. Hiramatsu, K. 1998. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am. J. Med. 104:7S-10S.
12. Hoellman, D. B., G. Lin, L. M. Ednie, A. Rattan, M. R. Jacobs, and P. C. Appelbaum. 2003. Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents. Antimicrob. Agents Chemother. 47:1148-1150.
13. Jones, R. N., T. R. Fritsche, and H. S. Sader. 2004. Antimicrobial spectrum and activity of NVP-PDF 713, a novel peptide deformylase inhibitor, tested against 1,837 recent gram-positive clinical isolates. Diagn. Microbiol. Infect. Dis. 49:63-65.
14. Jones, R. N., G. J. Moet, H. S. Sader, and T. R. Fritsche. 2004. Potential utility of a peptide deformylase inhibitor (NVP-PDF 713) against oxazolidinone-resistant or streptogramin-resistant gram-positive organism isolates. J. Antimicrob. Chemother. 53:804-807.
15. Jones, R. N., and P. R. Rhomberg. 2003. Comparative spectrum and activity of NVP-PDF386 (VCR4887), a new peptide deformylase inhibitor. J. Antimicrob. Chemother. 51:157-161.
16. Livermore, D. M. 2000. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J. Antimicrob. Chemother. 46:347-350.
17. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed.; approved standard. NCCLS publication no. M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Nichols, R. L. 1999. Optimal treatment of complicated skin and soft tissue infections. J. Antimicrob. Chemother. 44:19-23.
19. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1994. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin and vancomycin by using time-kill methodology. Antimicrob. Agents Chemother. 38:2065-2072.
20. Patel, R., M. S. Rouse, K. E. Piper, and J. M. Steckelberg. 1999. In-vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 34:119-122.
21. Snydman, D. R., N. V. Jacobus, L. A., McDermott, J. R. Lonks, and J. M. Boyce. 2000. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob. Agents Chemother. 44:3447-3450.
22. Stevens, D. L., L. G. Smith, J. B. Brass, M. A. McConnell-Martin, S. E. Duvall, W. M. Todd, and B. Hafkin. 2000. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 44:3408-3413.
23. Tenover, F. C., L. M. Weigel, P. C. Appelbaum, L. K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C. M. O'Hara, L. Jevitt, J. B. Patel, and B. Bozdogan. 2004. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48:275-280.
24. Voss, A., D. Milatovic, C. Wallrauch-Schwarz, V. T. Rosdahl, and I. Braveny. 1994. Methicillin-resistant Staphylococcus aureus in Europe. Eur. J. Clin. Microbiol. Infect. Dis. 13:50-55.